[{"id":"f2b35136-f790-410c-b54a-4f61af16101b","acronym":"ZWI-ZW25-101","url":"https://clinicaltrials.gov/study/NCT02892123","created_at":"2021-01-17T17:13:28.525Z","updated_at":"2024-07-02T16:35:08.789Z","phase":"Phase 1","brief_title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","source_id_and_acronym":"NCT02892123 - ZWI-ZW25-101","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" EGFR • HER-2 • KRAS • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion","tags":["EGFR • HER-2 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-18"},{"id":"258dd981-3155-4a65-b439-66d48123d14a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020457","created_at":"2021-08-25T14:53:14.347Z","updated_at":"2024-07-02T16:35:21.410Z","phase":"Phase 2","brief_title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","source_id_and_acronym":"NCT05020457","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • paclitaxel • docetaxel • pemetrexed • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-01-31"},{"id":"8c304df1-30b9-42ae-94a2-7c26d92108b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03656094","created_at":"2021-01-18T17:56:44.623Z","updated_at":"2024-07-02T16:36:52.774Z","phase":"Phase 2","brief_title":"Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors","source_id_and_acronym":"NCT03656094","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • pemetrexed • vinorelbine tartrate"],"overall_status":"Unknown status","enrollment":" Enrollment 98","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-12-09"},{"id":"16c5ddd2-0653-4f1d-871d-018e5ea1af84","acronym":"","url":"https://clinicaltrials.gov/study/NCT03282435","created_at":"2021-01-18T16:13:25.121Z","updated_at":"2024-07-02T16:37:17.903Z","phase":"Phase 1","brief_title":"Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody","source_id_and_acronym":"NCT03282435","lead_sponsor":"Dalian University","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2017-09-14"},{"id":"f4488597-414b-4206-9df3-12afd90921ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT02804646","created_at":"2021-01-18T13:45:10.328Z","updated_at":"2024-07-02T16:37:31.130Z","phase":"Phase 4","brief_title":"Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT02804646","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type • ALK negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Endostar (recombinant human endostatin)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-06-21"}]